Chris Diehnelt, Ph.D.

Chris brings 15 years of experience in design and development of peptide microarray assays with 30 publications and 9 patents. He directed a peptide microarray research group and core facility at ASU that developed multiple commercialized peptide microarray based technologies. He received his Ph.D. in Analytical Chemistry from Texas A&M University and has worked in private, government and academic institutions including Waters Corporation, the US EPA, and UT Southwestern Medical Center. Chris is Founder and CEO of Robust Diagnostics, a CRO providing high-resolution antibody assays to advance vaccine and drug development.